SAL-0951

Phase 3Small molecule

SShenzhen Salubris Pharmaceuticals Co., Ltd.

SAL-0951 is one of 69 small molecule programs targeting Anemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnemiaActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

AnemiaPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

SAL-0951

SShenzhen Salubris Pharmaceuticals Co., Ltd.

Phase 3

1 4

Sovaldi

Gilead

Preclinical

1 5

Glucotrol

Pfizer

Preclinical

1 6

Lorelco

Sanofi

Preclinical

1 7

Flomax

Epoetin Beta

5 9

Genotropin

EMD Serono

Preclinical

1 10

Januvia

ZZydus Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anemia2 trials

Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis

Completed·SShenzhen Salubris Pharmaceuticals Co., Ltd.·Phase 3·NCT06720233·37 enrolled

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

Recruiting·SShenzhen Salubris Pharmaceuticals Co., Ltd.·Phase 2·NCT06737081·60 enrolled

Erythropoietin1 trial

Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis

Completed·SShenzhen Salubris Pharmaceuticals Co., Ltd.·Phase 3·NCT06720025·100 enrolled

Chronic Kidney Disease1 trial

SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease

Completed·SShenzhen Salubris Pharmaceuticals Co., Ltd.·Phase 3·NCT06016036·156 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SAL-0951. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAL-0951 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAL-0951. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen Salubris Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShenzhen Salubris Pharmaceuticals Co., Ltd.

SAL-0951

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anemia2 trials

Erythropoietin1 trial

Chronic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News